Patterns of Bisphosphonates Utilization in Patients under Age 45 in a Large Cohort of Commercial Insurance Beneficiaries in the United States

por Xie, Jing, Tong, Angela, Kim, Seoyoung C.
Publicado 2015

Misclassification of Obesity in Claims Data

por Suissa, Karine, Kim, Seoyoung C., Patorno, Elisabetta
Publicado 2021

Real-world patterns of pegloticase use for treatment of gout: descriptive multidatabase cohort study

por Chen, Sarah K, Liu, Jun, Kim, Seoyoung C
Publicado 2020

Patterns of health care utilization related to initiation of amitriptyline, duloxetine, gabapentin, or pregabalin in fibromyalgia

por Kim, Seoyoung C, Landon, Joan E, Lee, Yvonne C
Publicado 2015

Real‐World Treatment Effectiveness of Disease‐Modifying Antirheumatic Drugs by Serostatus Among Patients With Rheumatoid Arthritis

por Jin, Yinzhu, Liu, Jun, Desai, Rishi J., Kim, Seoyoung C.
Publicado 2023

Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research

por Levin, Philip A, Nguyen, Hiep, Wittbrodt, Eric T, Kim, Seoyoung C
Publicado 2017

Risk of Non-Vertebral Fracture in Gout Compared to Rheumatoid Arthritis

por Cho, Soo-Kyung, Liu, Jun, Jin, Yinzhu, Kim, Seoyoung C.
Publicado 2021

Combined Conventional Synthetic Disease Modifying Therapy vs. Infliximab for Rheumatoid Arthritis: Emulating a Randomized Trial in Observational Data

por Barbulescu, Andrei, Askling, Johan, Saevarsdottir, Saedis, Kim, Seoyoung C., Frisell, Thomas
Publicado 2022

Comparative Risk of Diabetes Mellitus in Patients With Rheumatoid Arthritis Treated With Biologic or Targeted Synthetic Disease‐Modifying Drugs: A Cohort Study

por Desai, Rishi J., Dejene, Sara, Jin, Yinzhu, Liu, Jun, Kim, Seoyoung C.
Publicado 2020

Use of biologic or targeted-synthetic disease-modifying anti-rheumatic drugs and risk of diabetes treatment intensification in patients with rheumatoid arthritis and diabetes melli...

por Chen, Sarah K, Lee, Hemin, Jin, Yinzhu, Liu, Jun, Kim, Seoyoung C
Publicado 2020

Updated Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol

por Pawar, Ajinkya, Desai, Rishi J., Liu, Jun, Kim, Erin, Kim, Seoyoung C.
Publicado 2021

Comparative Risk of Nonvertebral Fractures Among Patients With Rheumatoid Arthritis Treated With Biologic or Targeted Synthetic Disease‐Modifying Antirheumatic Drugs

por Pawar, Ajinkya, Desai, Rishi J., He, Mengdong, Bessette, Lily, Kim, Seoyoung C.
Publicado 2021

Human Papillomavirus Vaccine Uptake among Individuals with Systemic Inflammatory Diseases

por Feldman, Candace H., Hiraki, Linda T., Lii, Huichuan, Seeger, John D., Kim, Seoyoung C.
Publicado 2015

Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis

por Jin, Yinzhu, Desai, Rishi J., Liu, Jun, Choi, Nam-Kyong, Kim, Seoyoung C.
Publicado 2017

Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis

por Kaze, Arnaud D., Zhuo, Min, Kim, Seoyoung C., Patorno, Elisabetta, Paik, Julie M.
Publicado 2022

Risk of Uveitis in Patients With Inflammatory Bowel Disease on Immunosuppressive Drug Therapy

por Barberio, Julie, Kim, Seoyoung C, Roh, Miin, Lewis, James D, Desai, Rishi J
Publicado 2020

An external validation study reporting poor correlation between the claims-based index for rheumatoid arthritis severity and the disease activity score

por Desai, Rishi J, Solomon, Daniel H, Weinblatt, Michael E, Shadick, Nancy, Kim, Seoyoung C
Publicado 2015

Cardiovascular risk associated with allopurinol vs. benzbromarone in patients with gout

por Kang, Eun Ha, Park, Eun Hye, Shin, Anna, Song, Jung Soo, Kim, Seoyoung C
Publicado 2021

Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study

por Fralick, Michael, Kim, Seoyoung C, Schneeweiss, Sebastian, Everett, Brendan M, Glynn, Robert J, Patorno, Elisabetta
Publicado 2020

Patient characteristics associated with use of TNF vs interleukin inhibitors as first-line biologic treatment for psoriatic arthritis

por Jin, Yinzhu, Chen, Sarah K, Lee, Hemin, Landon, Joan E, Merola, Joseph F, Kim, Seoyoung C
Publicado 2021